Major response to imatinib mesylate in KIT-mutated melanoma.
Hodi
F Stephen
FS
The Melanoma Program, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Friedlander
Philip
P
Corless
Christopher L
CL
Heinrich
Michael C
MC
Mac Rae
Suzanne
S
Kruse
Andrea
A
Jagannathan
Jyothi
J
Van den Abbeele
Annick D
AD
Velazquez
Elsa F
EF
Demetri
George D
GD
Fisher
David E
DE
D000368:Aged; D000714:Anastomosis, Surgical / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D008545:Melanoma / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery; D009154:Mutation; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D009366:Neoplasm Seeding; D010879:Piperazines / Q000627:therapeutic use*; D019009:Proto-Oncogene Proteins c-kit / Q000235:genetics*; D011743:Pyrimidines / Q000627:therapeutic use*; D012004:Rectal Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000601:surgery
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D019009:Proto-Oncogene Proteins c-kit